• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
NewslettersBrainstorm Health

A Promising Pair of Ebola Drugs Raises Hopes in Africa: Brainstorm Health

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
August 12, 2019, 7:26 PM ET

Happy Monday, readers! I hope you had a wonderful weekend.

Let’s start off the week with a bit of positive news. A pair of experimental Ebola treatments have proven successful enough that they’ll be administered to all patients in the Congo, the National Institutes of Health said on Monday.

“Very encouraged that 2 arms of study in the DRC testing experimental treatments for #Ebola show that REGN-EB3 or mAb114 substantially benefited patients. All future patients will now receive either, in what will be an extension phase of the study,” wrote NIH director Francis Collins in a tweet.

Let’s break that down into simpler terms. The two treatments in question (REGN-EB3 and mAb114) are being developed, respectively, by the pharmaceutical giant Regeneron and the startup Ridgeback Biotherapeutics (although the latter was licensed mAb114, a monoclonal antibody, from the NIH itself).

Here’s the thing—these two Ebola cure wannabes have proven effective enough (and amid a devastating, difficult-to-contain outbreak in the Congo)—that global health officials believe local residents will actually be willing to take them. It’s a matter of trust fueled by (admittedly preliminary) efficacy.

Read on for the day’s news.

Sy Mukherjee, @the_sy_guy, sayak.mukherjee@fortune.com

INDICATIONS

Congress has noticed Novartis' data issues for its gene therapy. Drug giant Novartis continues to face the fallout from its data manipulation scandal for a $2.1 million gene therapy treatment called Zolgensma, Reuters reports. Sen. Chuck Grassley, chairman of the U.S. Senate Finance Committee, is seeking more information from the company regarding its internal investigations into alleged data manipulations (allegations which led the FDA to threaten potential criminal charges). Novartis CEO Vas Narasimhan said last week that the company had "tried to do the right things" with regards to the data issues, and that the employees involved in the matter were being removed. (Reuters)

THE BIG PICTURE

An American abroad is being accused of running an unlicensed medical facility. A U.S. citizen is being accused of operating a non-profit in Uganda meant to treat malnourished children that, according to the allegations, actually led to the deaths of hundreds of children. Renee Bach, a missionary, strongly denied those allegations to NBC News—while also admitting that more than 100 children died at the facility she operated. (NBC News)

REQUIRED READING

What the IRS Wants You to Know About Tax Scams, by The Associated Press

Tiny Luxembourg Is Having a Big Brexit Moment, by Josie Cox

Um, Where's the Recession? by Polina Marinova

Rite Aid Names New CEO, Brings Number of Women CEOs on Fortune 500 to Record High, by Bloomberg

Find past coverage. Sign up for other Fortune newsletters.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon

Latest in Newsletters

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Most Popular

placeholder alt text
Economy
America's $38 trillion national debt 'exacerbates generational imbalances' with Gen Z and millennials paying the price, warns think tank
By Eleanor PringleDecember 16, 2025
1 day ago
placeholder alt text
Success
Meetings are not work, says Southwest Airlines CEO—and he’s taking action, by blocking his calendar every afternoon from Wednesday to Friday 
By Preston ForeDecember 15, 2025
2 days ago
placeholder alt text
Innovation
An MIT roboticist who cofounded bankrupt Roomba maker iRobot says Elon Musk's vision of humanoid robot assistants is 'pure fantasy thinking'
By Marco Quiroz-GutierrezDecember 16, 2025
1 day ago
placeholder alt text
Success
'I had to take 60 meetings': Jeff Bezos says 'the hardest thing I've ever done' was raising the first million dollars of seed capital for Amazon
By Dave SmithDecember 15, 2025
2 days ago
placeholder alt text
Success
As millions of Gen Zers face unemployment, McDonald's CEO dishes out some tough love career advice for navigating the market: ‘You've got to make things happen for yourself’
By Preston ForeDecember 16, 2025
24 hours ago
placeholder alt text
Banking
Trump turns on CBS, Kushner pulls out and Paramount's hostile bid for Warner Bros. shows signs of collapse
By Eva RoytburgDecember 16, 2025
17 hours ago

Latest in Newsletters

Team of executives talking in a meeting in the office.
NewslettersCFO Daily
CFO confidence rebounds, but delivering AI’s value is the next test in 2026
By Sheryl EstradaDecember 17, 2025
3 hours ago
NewslettersTerm Sheet
Databricks CEO Ali Ghodsi on where AI is most bubbly, and how the company settled on its $134 billion valuation
By Allie GarfinkleDecember 17, 2025
3 hours ago
Databricks co-founder and CEO Ali Ghodsi (left) with Fortune editorial director Andrew Nusca at Fortune Brainstorm AI 2025 in San Francisco. (Photo: Stuart Isett/Fortune)
NewslettersFortune Tech
Databricks is now worth $134 billion
By Andrew NuscaDecember 17, 2025
4 hours ago
NewslettersCEO Daily
Why more boards are taking a chance on outsider CEOs
By Geoff ColvinDecember 17, 2025
5 hours ago
A group of three robots waiving hello to the audience from a stage.
AIEye on AI
Google researchers unlock some truths about getting AI agents to actually work
By Jeremy KahnDecember 16, 2025
19 hours ago
NewslettersMPW Daily
Meet the top female execs who are poised to take over the Fortune 500
By Emma HinchliffeDecember 16, 2025
23 hours ago